All In Biotech

BLA 103234 · Amgen

Epogen/Procrit

Epoetin Alfa · Single-Use, Multidose

NovelOrphan

Last checked: Nov 20, 2026Latest source record: Apr 30, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1989

Jun 1, 1989

Approved uses

7

Original approval plus efficacy supplements

Registered trials

593

243 Phase 3, 14 recruiting

FAERS reports

32,014

23,349 serious, 6,846 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: ESAs INCREASE THE RISK OF DEATH, MYOCARDIAL INFARCTION, STROKE, VENOUS THROMBOEMBOLISM, THROMBOSIS OF VASCULAR ACCESS AND TUMOR PROGRESSION OR RECURRENCE Chronic Kidney Disease: In controlled trials, patients with chronic kidney disease (CKD) experienced greater risks for death, serious adverse cardiovascular reactions, and stroke when administered erythropoiesis-stimulating agents (ESAs) to target a hemoglobin level of greater than 11 g/dL [see Warnings and Precautions ( 5.1 )] . No trial has identified a hemoglobin target level, E SA dose, or dosing strategy that does not increase these risks [see Dosage and Administration ( 2.2 )] . Use the lowest Epogen dose sufficient to reduce the need for red blood cell (RBC) transfusions [see Warnings and Precautions ( 5.1 )] . Cancer: ESAs shortened overall survival and/or increased the risk of tumor progression or recurrence in...

What it is approved for

From the label in effect Jun 23, 2026.

Epogen is an erythropoiesis-stimulating agent (ESA) indicated for: Treatment of anemia due to: - Chronic Kidney Disease (CKD) in patients on dialysis and not on dialysis ( 1.1 ). - Zidovudine in patients with Human Immunodeficiency Virus (HIV) infection ( 1.2 ). - The effects of concomitant myelosuppressive chemotherapy, and upon initiation, there is a minimum of two additional months of planned chemotherapy ( 1.3 ). Reduction of allogeneic red blood cell (RBC) transfusions in patients undergoing elective, noncardiac, nonvascular surgery ( 1.4 ). Limitations of Use Epogen has not been shown to improve quality of life, fatigue, or patient well-being ( 1.5 ). Epogen is not indicated for use: In patients with cancer receiving hormonal agents, biologic products, or radiotherapy, unless also receiving concomitant myelosuppressive chemotherapy ( 1.5 ). In patients with cancer receiving myelosuppressive chemotherapy when the anticipated outcome is cure ( 1.5 ). In patients with cancer receiving myelosuppressive chemotherapy in whom the anemia can be managed by transfusion ( 1.5 ). In patients scheduled for surgery who are willing to donate autologous blood ( 1.5 ). In patients undergoing cardiac or vascular surgery ( 1.5 ). As a substitute for RBC transfusions in patients who require immediate correction of anemia ( 1.5 ). 1.1 Anemia Due to Chronic Kidney Disease Epogen is indicated for the treatment of anemia due to chronic kidney disease (CKD), including patients on dialysis and not on dialysis to decrease the need for red blood cell (RBC) transfusion. 1.2 Anemia Due to Zidovudine in Patients with HIV Infection Epogen is indicated for the treatment of anemia due to zidovudine administered at ≤ 4200 mg/week in patients with HIV infection with endogenous serum erythropoietin...

Mechanism: Epogen stimulates erythropoiesis by the same mechanism as endogenous erythropoietin.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jun 24, 2011 Supplement 5166 · Efficacy LabelReviewSummary Review
  • Oct 27, 2005 Supplement 5082 · Efficacy
  • Jun 30, 2004 Supplement 5053 · Efficacy LabelReviewLetter
  • May 21, 2004 Supplement 5033 · Efficacy ReviewLetter
  • Dec 23, 1996 Supplement 1036 · Efficacy
  • Apr 1, 1993 Supplement 1015 · Efficacy Label
  • Jun 1, 1989 Original approval · Type 1 - New Molecular Entity
7 products under this application
  • EPOGEN/PROCRIT · EPOETIN ALFA 40,000U/ML · VIAL, SINGLE-USE · Prescription
  • EPOGEN/PROCRIT · EPOETIN ALFA 2,000U/ML · VIAL, SINGLE-USE · Prescription
  • EPOGEN/PROCRIT · EPOETIN ALFA 20,000U/2ML · VIAL, MULTIDOSE · Prescription
  • EPOGEN/PROCRIT · EPOETIN ALFA 4,000U/ML · VIAL, SINGLE-USE · Prescription
  • EPOGEN/PROCRIT · EPOETIN ALFA 3,000U/ML · VIAL, SINGLE-USE · Prescription
  • EPOGEN/PROCRIT · EPOETIN ALFA 20,000/ML · VIAL, MULTIDOSE · Prescription
  • EPOGEN/PROCRIT · EPOETIN ALFA 10,000U/ML · VIAL, SINGLE-USE · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Epoetin Alfa" as an intervention, any sponsor and status, largest first.

All 593 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • death3,119
  • anaemia2,266
  • haemoglobin decreased1,988
  • fatigue1,838
  • diarrhoea1,557
  • nausea1,552
  • asthenia1,494
  • dyspnoea1,469
  • off label use1,416
  • product storage error1,292
  • pain1,176
  • pneumonia1,175

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004881
2005934
20061,498
20071,330
20081,200
20091,281
20101,330
20111,150
20121,790
20131,872
20141,474
20151,981
20161,981
20172,027
20181,903
20191,484
20201,224
20211,177
20221,546
20231,352
20241,310
2025813
2026476

Recalls

2 FDA enforcement reports for this application.

  • Sep 13, 2017 · Class II · Terminated

    Presence of particulate matter: glass flakes identified as lamellae observed during a routine quality inspection.

  • Aug 4, 2017 · Class II · Terminated

    Presence of particulate matter: Visible glass flakes identified as lamellae in some drug product vials.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 345 on PubMed

Sponsor: Amgen

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.